pennystockhaven
  • Facebook
  • Twitter
  • Youtube
  • Rss
Day-Trading Penny Stocks
  • Home
  • Services
  • Contact Us
Home» Commentary » pSivida Corp. (PSDV): ILUVIEN MA Granted vs $40M Equity Financing

pSivida Corp. (PSDV): ILUVIEN MA Granted vs $40M Equity Financing

Posted on July 19, 2012 by PennyStockHaven in Commentary, Stock Market Movers & Losers, Stock Market News - No Comments

pSivida Corp. (PSDV) today announced the National Security Agency of Medicines and Health Products (L’Agence Nationale de Sécurité du Médicament et des Produits de Santé) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

Dr. Paul Ashton, President and CEO of pSivida, commented:

We are pleased our product has received marketing authorization in France. We now have marketing authorization in four of the seven targeted EU countries,” said . “We look forward to ILUVIEN receiving approval in the three remaining CMS countries, Germany, Italy and Spain, in the coming months.

Great news but keep in mind that yesterday the pSivida’s partner, Alimera Sciences, disclosed an agreement for a $40 million equity financing for the development and commercialization of ILUVIEN®. Alimera reported that proposed financing is subject to customary closing conditions and shareholders approval.

Most likely the offering will not be in favor of PSDV’ common shareholders judging by the pSivida’s financial conditions.

Nasdaq penny markets PSDV logoCorporate Headquarters:
400 Pleasant Street
Watertown MA 02472
Tel: (617) 926-5000
Fax: (617) 926-5050
http://www.psivida.com/

pSivida is a leader in the development of miniaturized, injectable, drug delivery systems. Company develops products to treat serious or life threatening diseases alone or in partnership with other companies. It has developed devices that are so small they are FDA approved to be administered into the eye and once administered they release their drug for months and years.

biopharma news, PSDV, pSivida Corp

Search

Real Time Alerts:

Tweets by @PennyStockHaven

Updates

  • CVR Partners, LP (NYSE: UAN): the dividend play

    February 26, 2023
  • Sotera Health

    Sotera Health Company (NASDAQ:SHC): hard road ahead

    February 21, 2023
  • ZIM Integrated Shipping Services (NYSE:ZIM) uphill movement

    February 20, 2023
  • Carvana Co. (NYSE: CVNA) way to go… down

    February 17, 2023
  • ReWalk Robotics (RWLK): Yesterday, Today and Tomorrow

    June 8, 2019
  • Amyris, Inc. (AMRS): How to Mislead Investors

    April 21, 2019
  • ADMA Biologics, Inc. (ADMA): Offering is Imminent

    April 11, 2019
  • Proteostasis Therapeutics (PTI): Market Overreaction

    March 26, 2019
  • Dynagas LNG Partners LP (NYSE: DLNG) Coming Off Of Bottom

    February 1, 2019
  • Histogenics Corporation (HSGX) market: only upside from these levels

    September 5, 2018
  • Quantum Corp. (QTM): Appointed Jamie Lerner as Chief Executive Officer and President

    June 26, 2018
  • FuelCell Energy (NASDAQ:FCEL) A picture is worth a thousand words

    June 22, 2018

    Site

    • Home
    • Services
    • Contact Us
    • About Us
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    • Publishers

    Financial Network

    Yahoo Finance
    Reuters
    The Motley Fool
    WSJ
    CNBC
    Business Week
    The Street
    Bloomberg

    psh sloganYour Everything Penny Stocks Resource



    Copyright © 2021 PennyStockHaven.com. All Rights Reserved